Luspatercept
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-LUSPATERCEPT |
|---|---|
| Type | Drug |
| Aliases | ReblozylЛуспатерцепт |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-MDS-LR |
| Sources | SRC-COMMANDS-FENAUX-2020 SRC-ESMO-MDS-2021 SRC-NCCN-AML-2025 |
Drug Facts
| Class | Erythroid maturation agent (TGF-β superfamily ligand trap) |
|---|---|
| Mechanism | Recombinant fusion protein binding select TGF-β superfamily ligands (GDF11, activin B), promotes late-stage erythroid maturation in MDS and β-thalassemia. Reduces transfusion burden in lower-risk MDS with ring sideroblasts and (per COMMANDS) in non-RS LR-MDS as 1L vs ESA. |
| Typical dosing | MDS / β-thalassemia: 1.0 mg/kg SC every 3 weeks; titrate to 1.33 mg/kg then 1.75 mg/kg if no transfusion-burden reduction after 2 doses. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Lower-risk MDS with RS and RBC TD post-ESA failure (MEDALIST) — TI ≥8 wk 38% vs 13% placebo. COMMANDS trial established luspatercept as 1L over ESA for transfusion-dependent LR-MDS broadly. NOT registered in Ukraine.
Used By
Regimens
REG-LUSPATERCEPT-MDS-LR- Luspatercept (MDS-LR with RS or post-ESA failure)